[2]
Das Choudhury, J.; Kumar, S.; Mayank, V.; Mehta, J.; Berdalai, D. A review on apoptosis & its different pathway. Int. J. Biol. Pharm. Res., 2012, 3, 848-861.
[6]
Cade, C.E.; Clark, A.C. Caspases – Key Players in Apoptosis.Proteases in Apoptosis: Pathways, Protocols and Translational Advances; Bose, K., Ed.; Springer: Cham, 2015, pp. 31-52.
[13]
Pavelka, K.; Kua, V.; Rasmussen, J.M.; Mikkelsen, K.; Tamasi, L.; Vitek, P.; Rozman, B. Clinical Effects of Pralnacasan (PRAL), an Orally-Active Interleukin-1beta Converting Enzyme (ICE) inhibitor, in a 285 patient PhII trial in rheumatoid arthritis. Sci. Open, 2002, 2002, 3415-3415.
[25]
Modeling, M.; Inhibitors, C. Multi-pharmacophore modeling of caspase-3 inhibitors using crystal, dock and flexible conformation schemes. Comb. Chem. High Throughput Screen., 2018, 21(1), 26-40.
[27]
Berendsen, H.J.C.; Postma, J.P.M.; van Gunsteren, W.F.; Hermans, J.; van Gunsteren, W.F. Interaction Models for Water in Relation to Protein Hydration. In: Intermolecular Forces; Pullman. B., Ed., 1981; pp. 331-338. [http://10.1007/978-94-015-7658-1_21]
[38]
Abdel-Ilah, L.; Veljovic, E.; Lejla, G.; Badnjevic, A. Applications of QSAR study in drug design. IJERT, 2017, 6, 582-587.
[41]
Powers, J.C.; Asgian, J.L.; James, K.E. PowersJC02ChemRev_SerCysThr irreversible inhibitor.Pdf 2002.
[50]
Manuscript, A. NIH Public Access., 2013, 69, 679-689.
[51]
Lee, D.; Long, S.A.; Adams, J.L.; Chan, G.; Vaidya, K.S.; Francis, T.A.; Kikly, K.; Winkler, J.D.; Sung, C.M.; Debouck, C.; Richardson, S.; Levy, M.A.; DeWolf, W.E., Jr; Keller, P.M.; Tomaszek, T.; Head, M.S.; Ryan, M.D.; Haltiwanger, R.C.; Liang, P.H.; Janson, C.A.; McDevitt, P.J.; Johanson, K.; Concha, N.O.; Chan, W.; Abdel-Meguid, S.S.; Badger, A.M.; Lark, M.W.; Nadeau, D.P.; Suva, L.J.; Gowen, M.; Nuttall, M.E.; Vaidya, K.S.; Francis, T.A.; Kikly, K.; Winkler, J.D.; Sung, C.; Debouck, C.; Richardson, S.; Levy, M.A.; Dewolf, W.E.; Keller, P.M.; Tomaszek, T.; Head, M.S.; Ryan, M.D.; Haltiwanger, R.C.; Liang, P.; Janson, C.A.; Mcdevitt, P.J.; Johanson, K.; Concha, N.O.; Chan, W.; Abdel-meguid, S.S.; Badger, A.M.; Lark, M.W.; Nadeau, D.P.; Suva, L.J.; Gowen, M.; Nuttall, M.E. Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality.
J. Biol. Chem., 2000,
275(21), 16007-16014.
[
http://dx.doi.org/10.1074/jbc.275.21.16007] [PMID:
10821855]
[54]
Amber, C. Amber 2018 Reference Manual. 2018.
[59]
Dastmalchi, S. Methods and algorithms for molecular docking-based. Drug Des. Discov., 2016, 456.
[60]
Johari, S.; Sinha, S.; Bora, S. Ligand Binding Studies of Caspase 3 Protein with Compounds of Bacopa Monneri - A Target Protein Responsible for Alzheimer’ s Disease (AD); Springer, 2012, pp. 37-43.
[73]
Prieto-Martínez, F.D.; Arciniega, M.; Medina-Franco, J.L. Acoplamiento Molecular: Avances Recientes y Retos. TIP Rev. Espec. en Ciencias Químico-Biológicas, 2018, 21, 65-87.
[81]
Qing, X.; Lee, X.Y.; De Raeymaeker, J.; Tame, J.R.; Zhang, K.Y.; De Maeyer, M.; Voet, A.R. Pharmacophore modeling: Advances, limitations, and current utility in drug discovery. J. Receptor Ligand Channel Res., 2014, 7, 81-92.
[86]
Lazarova, M. Virtual screening – models, methods and software systems. Int. Sci. Conf. Comput. Sci., 2008, 2008, 55-60.
[87]
Klopmand, G. Concepts and applications of molecular similarity, by Mark A. Johnson and Gerald M. Maggiora, Eds., John Wiley & Sons, New York, 1990, 393 Pp. Price: $65.00.J. Comput. Chem; , 1992, 13, pp. 539-540.
[95]
Morris, G.M.; Goodsell, D.S.; Pique, M.E.; Lindstrom, W.L.; Huey, R.; Hart, W.E.; Halliday, S.; Belew, R.; Olson, A.J. AutoDock Version 4.2; User Guid, 2009, pp. 1-49.
[100]
Smith, A.J.T.; Zhang, X.; Leach, A.G.; Houk, K.N. Beyond picormolar affinities: Quantitative aspects of noncovalent and covalent binding of drugs to proteins. J. Med., 2010, 52, 225-233.